A surge in therapeutic clinical trials over recent years is paving the way for transformative
treatment options for patients with hemophilia. The introduction of recombinant factor …

Hemophilia A, characterized by impaired or absent expression of factor VIII, has long been
managed via direct factor replacement. Functionally, factor VIII acts as a cofactor for factor …

Essentials• Recombinant factor VIII BAY 94‐9027 conjugates in a site‐specific manner with
polyethylene glycol.• BAY 94‐9027 was given to patients with severe hemophilia A as …

Background BAY 81‐8973 is a new full‐length human recombinant factor VIII product
manufactured with technologies to improve consistency in glycosylation and expression to …

Prophylactic therapy with exogenous clotting factor concentrates in haemophilia A and B
aims to achieve levels of circulating FVIII or FIX that are adequate for the prevention or …

Bleeding disorders are broadly classified into primary and secondary hemostatic defects
(Fig. 1). Primary hemostatic disorders (disorders of platelets and von Willebrand factor …

Current therapy for haemophilia A is guided by severity of the disease, which in turn is best
reflected in patients' endogenous factor VIII activity levels. For patients with severe …

Background The use of monthly recombinant factor XIII (rFXIII) recently demonstrated
favorable safety and efficacy for congenital FXIII A‐subunit deficiency patients aged≥ 6 …

Background: Although much attention has been paid to the pharmacokinetics (PKs) of
different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information …

Background Prophylaxis with factor VIII (FVIII) should be individualized based on patient
characteristics, including FVIII pharmacokinetics. Population pharmacokinetic (popPK) …